Free Daily Podcast Summary
Open Door Salon: Daily Summaries Delivered
by Open Door Salon
Open Door Salon is the life sciences podcast where the people building drug development, biotech investment and healthcare innovation talk on the record. Host Lori Ellis sits down with biotech and pharma executives, investors and regulators for unscripted conversations about what it takes to get new therapies to patients. Change starts with conversation.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- Today47 min
How China Became a Drug Pipeline for Big Pharma | Ying Huang & Ansbert Gadicke
Ying Huang, former CEO of Legend Biotech and now CEO of K2 Therapeutics, and Ansbert Gadicke, founder and managing partner of MPM BioImpact, join Open Door Salon to discuss how China became a source of new drugs for the global industry.They discuss why large drug companies first doubted Legend's data from China, why assets already tested in patients in China carry less risk, why K2 is based in Singapore, and why licensing has become the norm instead of acquisition. They also cover whether the bargain era is over, what US biotech founders should build, the new rules on Chinese assets in Washington and Beijing, and the diligence and trial standards that build trust.Ying Huang, PhD | Chief Executive Officer, K2 TherapeuticsYing Huang is chief executive officer of K2 Therapeutics, a Singapore-based biotech founded in 2024 that licenses drug candidates from around the world, including China, and develops them to global standards. He was previously chief executive officer of Legend Biotech, which he joined as chief financial officer in 2019, and helped lead the development and launch of the cell therapy Carvykti with Johnson & Johnson. Before Legend he was managing director and head of biotech equity research at BofA Securities, after starting his career as a principal scientist at Schering-Plough. He holds a PhD in bio-organic chemistry from Columbia University.LinkedIn: https://www.linkedin.com/in/ying-huang-74ba092/Ansbert Gadicke, MD | Founder and Managing Partner, MPM BioImpactAnsbert Gadicke is founder and managing partner of MPM BioImpact, the biotech venture firm he started in 1992. Trained as a physician, he did research at the German Cancer Research Center, at Harvard University and at the Whitehead Institute for Biomedical Research at MIT, and worked as a consultant at The Boston Consulting Group before founding MPM. He has been a lead investor and board member at companies including BioMarin, Pharmasset, Cullinan Therapeutics, ElevateBio, Orna Therapeutics and K2 Therapeutics. He serves on the Harvard Medical School Board of Fellows and holds an MD from Goethe University Frankfurt.LinkedIn: https://www.linkedin.com/in/ansbert-gadicke-m-d-2437b5/ Why no one believed Legend's China data From Legend to K2: a Singapore hub-and-spoke model Why licensed Chinese assets lower development risk China's biotech ecosystem, and whether India can match it Licensing over acquisition, and the end of the bargain era Founder expectations, and how US biotechs can compete New rules on Chinese assets in Washington and Beijing Diligence when a partner could become restricted Trial deaths, FDA audits and what has to go right What drew them to this work The hardest challenges of their careers
- 1 weeks ago43 min
Why Stolen Biotech Research Rarely Ends Up in Court | Theresa Campobasso & Clinton West
Theresa Campobasso and Clinton West return to Open Door Salon. Campobasso is chief strategy officer of Reinaert and a former U.S. Marine Corps intelligence officer. West is Reinaert's president of supply chain security and logistics operations and a former CIA supply chain risk leader.They discuss the Beam Therapeutics lawsuit and the insider risk signals that could catch a case like it earlier, how a faster foreign patent office lets stolen research win the patent race, why IP theft cases rarely reach court, the due diligence investors skip, and what a breach at a venture firm exposes.Theresa Campobasso | Chief Strategy Officer, ReinaertTheresa Campobasso is chief strategy officer of Reinaert, a service-disabled, veteran-owned firm that provides security, logistics and mission support to government and commercial clients. A former U.S. Marine Corps intelligence officer, she served overseas in support of special forces in Afghanistan and later helped stand up the Defense Intelligence Agency's first Acquisition Risk Task Force. Before Reinaert she was SVP for strategic accounts at Exiger and a partner and SVP at Aardwolf Global Solutions. She is a Certified Insider Threat Program Manager and holds degrees from the University of Notre Dame and Georgetown University.LinkedIn: https://www.linkedin.com/in/theresa-campobasso-02b78b56/Clinton West | President, Supply Chain Security and Logistics Operations, ReinaertClinton West is president of supply chain security and logistics operations at Reinaert, a service-disabled, veteran-owned firm that provides security, logistics and mission support to government and commercial clients. He spent more than two decades at the Central Intelligence Agency, where he led the Office of Supply Chain Risk Management. Earlier he served in the U.S. Navy and at the National Reconnaissance Office. Before Reinaert he led the supply chain security practice at Aardwolf Global Solutions. He traces his interest in supply chain security to moving cargo in Somalia early in his career.LinkedIn: https://www.linkedin.com/in/clinton-west-jr/ The Beam Therapeutics case and three insider risk signals How a faster foreign patent office wins the race Why IP theft cases are so hard to win in court Sources and methods, and the diligence companies skip When an investor withholds capital: economic statecraft When a VC's portfolio company is breached Congress, Treasury and Section 1260H compliance What this career asked that they did not expect What the career cost them
- 3 weeks ago42 min
How Health Systems Decide Which AI to Buy | Paul Uhrig & Eddie Qureshi
Paul Uhrig is a healthcare lawyer and digital health executive, formerly Chief Legal and Digital Health Officer at Bassett Healthcare Network and Chief Administrative, Legal and Privacy Officer at Surescripts. Eddie Qureshi is founder and CEO of Rainfall Health, an AI platform that helps hospitals manage Medicare's TEAM model.They explain what health system executives ask before they buy AI, why so many pilots never reach scale, and why only two or three priorities ever make a C-suite agenda. Then the patient side: people connecting their medical records to ChatGPT and Claude, why that data falls outside HIPAA, the consent screens nobody reads, the 30 days after surgery, and why ambient listening stuck with clinicians. The consent form nobody reads AI, bad actors and the threat closer to home Cybersecurity and the 100% landing rule What executives ask before they buy AI Why pilots fail to scale Pitch versus pain point Is every health system the same? Patients bring AI to the exam room Patient data in consumer AI tools HIPAA, the FTC and who educates patients The 30 days after surgery 85% of health systems use AI Why ambient listening stuck What inspired their career paths The hardest decision or challenge
- 4 weeks ago51 min
What Cell and Gene Therapy Investors Need to See First | Phil Vanek & David Crean
Phil Vanek, PhD, is Chief Commercialization Officer of the International Society for Cell & Gene Therapy (ISCT), chair of the CGT Catapult Technology Advisory Board and founder of Redline Bioadvisors. David H. Crean, PhD, MBA, is founder and managing partner of Cardiff Advisory and the author of Dual Fluency.They explain what a cell and gene therapy founder has to show before an investor conversation goes anywhere: a de-risked asset, evidence the biology is real, and a manufacturing plan that is not left to the appendix. They argue for writing the target product profile first, rank capital, reimbursement and manufacturing cost, compare how the US, the UK and Europe pay for advanced therapies, and explain why deals announced at JPM start many months earlier. What founders have to show before the conversation starts Target product profile: write the label first Show me the data: AI, fabricated evidence, and the three pillars ranked Who pays: reimbursement in the US, UK and Europe The four-legged stool and the aducanumab lesson Should you build to be acquired? Who really picks the asset Why JPM deals start nine months earlier Hardening the supply chain, and why science needs capital fluency Career lessons, and killing a program that works Mentorship and advice for emerging founders
- Sep 30, 202648 min
Is Your Biotech a National Security Target? | Chad Raduege
Retired Air Force Brigadier General Chad Raduege spent 29 years in communications, IT and cyber operations, commanded the White House Communications Agency, and finished his career as Director of C4/Cyber and CIO for U.S. European Command. Today he is President of Cyber, Data & Communications at Elara Nova.He explains why he sees biopharma data as a national security matter, how ransomware differs from espionage by advanced persistent threats, and why the CEO owns cyber risk at a 40-person biotech with no CISO. He describes what an adversary could learn from a venture firm's due diligence files, how he reads the summer's incidents at Amgen, Boston Scientific and McKesson, and why the industry should build security in and share what it learns. First to market, first breached, and meet Chad Raduege Taking the Oval Office anywhere: the White House Communications Agency EUCOM: Afghanistan, COVID and Russia's invasion of Ukraine Where biopharma sits on a nation-state target list Ransomware vs. espionage, and the 40-person biotech with no CISO VC diligence files, accountability and crown jewels Amgen, Boston Scientific, McKesson: an adversary mapping the industry Build it in, don't strap it on, and the path to 29 years Stop casting stones: ISACs and learning together
- Sep 23, 202648 min
Why Digital Twins Won't Replace Patients | Nindhana Paranthaman & Paul Agapow
AI arrived in drug development carrying a very large promise. Nindhana Paranthaman, Vice President of Early Clinical Development at Bicara Therapeutics, and Paul Agapow, Chief Scientific Officer at Bayezian, work on opposite sides of that promise and agree on more than the marketing would suggest.Paranthaman names the gains that actually arrived, all of them operational, and the one that did not: more drugs advancing into the clinic. Agapow explains why a trial completed inside a year is marketing, takes the digital twin apart on logical rather than technical grounds, and estimates that about a third of what the industry is building today will still be standing in five years. They close on target herding and what an investor should ask an AI-first company. What AI actually delivered in clinical development Whether a one-year trial is marketing spin Digital twins, and why a twin cannot replace a patient What survives five years, and the breakdown Protocols, amendments and the unglamorous gold Why biology breaks AI: discovered, not invented Target herding and the hundredth me-too drug Advice for VCs, family offices and private equity
- Sep 16, 20261h 4m
What Gets a Biotech Pitch Funded: Mike Goguen and Christian Schubert
Six hundred investable opportunities in a year. Five investments. Christian Schubert, Vice President and Global Head of AbbVie Ventures, walks Lori Ellis through where the other 595 fall out, and almost none of it is about pitch quality.Mike Goguen joins him from the other end of the market. He spent twenty years as a general partner at Sequoia Capital before founding Two Bear Capital in 2019, and has served on more than eighty company boards.Two investors, two entirely different mandates, one table. They cover what separates a funded biotech pitch from a passed one, what loses a pitch inside the first twenty minutes, whether warm introductions still move a founder to the front of the line, why the amount raised early was almost inversely correlated with success in Goguen's own look back at the data, and what makes a rejection useful instead of vague. Out of 600 opportunities, five investments The five to ten percent in the middle, where the work is Is the problem big enough? Why biotech is not tech Passion, resilience, and the North Star nobody else believes yet Sequoia in 1996: should we ever do life sciences again? The capital gap corporate venture is stepping into What is the fastest pitch you have ever lost? What loses a pitch in the first twenty minutes How much diligence goes into the team, not just the founder Social worker and fireman: what early stage leadership actually is When a founder should step aside, and who says it out loud Do warm introductions still move you to the front of the line? Why raising less money early correlates with bigger outcomes Groupthink: the biggest fallacy in venture capital What a fundable company looks like in 2027 and 2028 The anatomy of a useful no The fund dynamics hiding behind a rejection The hardest questions: a random walk into venture Three billion lines of code in every cell The choice that lingers Venture capitalist, philanthropist, first responder. Pick one.Mike Goguen is Founder and Managing Partner of Two Bear Capital.https://www.linkedin.com/in/michael-goguen-23314/Christian Schubert is Vice President and Global Head of AbbVie Ventures.https://www.linkedin.com/in/crs79/Episode page: https://opendoorsalon.com/what-gets-a-biotech-pitch-funded/
- Sep 2, 202647 min
Pivot or Close: What the Last 90 Days of a Biotech Wind-Down Look Like
David Esposito has built biotechs to exit and taken biotechs into bankruptcy. Pavel Khrimian spent most of 2026 winding down the company he co-founded, after a pharma collaboration collapsed at the diligence stage. They talk about what the last ninety days actually look like, the three questions that separate a pivot from a closure, and the obligation to patients that outlives the company.Lori asks about the ninety days before the decision rather than the day of it, and both answers land in the same place: the data was there earlier, and it did not arrive labeled. A manufacturing delay. A term sheet that was supposed to be a hundred million, drops to eighty, then oversubscribes to a hundred and twenty five. A program that is performing but is no longer the priority.Khrimian reduces the closure decision to three questions. Do you have a credible hypothesis or asset. Do you have the cash to test it. Do you have the time and money to reach a realistic value inflection. Two answers of no and you are closing rather than pivoting. Esposito's version is structural: after a couple of rounds of capital a company has often prioritized itself into one swim lane, and the data then makes the decision for it.Neither treats the people as a footnote. Patients on therapy have to stay on therapy, which turns a wind-down into an operational problem of narrowing sites and continuing to ship drug. Employees who did nothing wrong need somewhere to land. Why founders are drawn back to biotech How this sponsored episode worked Exits, launches, and companies taken into bankruptcy Letting go of the obsession with control Reading a new data point and deciding whether to pivot Pay attention to every data point, not just your own Build a base case, then watch it move The acute study, and the pivot to chronic indications Why it is always about the team Healthy tension between science, finance and strategy Doing everything right and still losing A word from Lab Thread The ninety days before the decision When a pharma collaboration collapses in diligence Optimism as a gear, measured against cash Pivot or close: the three questions The binary swim lane, and the calls that are never clear What the CAR-T pivot into autoimmune teaches You are not rewarded for a platform anymore Carrying the news Two hundred grand in the bank and no January calendar Investors, patients, and your team at the same time Take your own shoes off first The obligation to patients still on therapy Helping your team land somewhere good What inspired you to take this path The hardest decision you have had to make Thank yousDavid Esposito is President and Chief Executive Officer of ONL Therapeutics.https://www.linkedin.com/in/davidesposito2/Pavel Khrimian is Co-founder and Chief Business Officer of Deka Biosciences.https://www.linkedin.com/in/pavel-khrimian-3219935/This episode was made possible by Lab Thread.Nobody went into science for the admin. Lab Thread is the integrated lab management platform that scientists actually enjoy; Built to fit the way you work, from first idea to final report. Everything connected. Nothing lost. Never in your way.Visit labthread.com to learn more, or book a demoEpisode page: https://opendoorsalon.com/biotech-wind-down-pivot-or-close/Newsletter: https://opendoorsalon.substack.com/
About Open Door Salon
Open Door Salon is the life sciences podcast where the people building drug development, biotech investment and healthcare innovation talk on the record. Host Lori Ellis sits down with biotech and pharma executives, investors and regulators for unscripted conversations about what it takes to get new therapies to patients. Change starts with conversation.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from Open Door Salon in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's Open Door Salon daily summary?
It's a free AI-powered email that summarizes new episodes of Open Door Salon as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the Open Door Salon podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official Open Door Salon product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by Open Door Salon.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts, any in the catalog. Basic raises that to 15, Pro to 40 and Max to 100. Browse our full catalog at /podcasts.
What topics does Open Door Salon cover?
Open Door Salon covers topics including Science, Medicine, Fitness, Health & Fitness, Life Sciences. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting Open Door Salon summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.